Caution for interstitial lung disease as a cause of CA 15‐3 rise in advanced breast cancer patients treated with everolimus

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 135; no. 4; p. 1007
Main Authors Willemsen, Annelieke E.C.A.B., Grutters, Jan C., Gerritsen, Winald R., Tol, Jolien, Herpen, Carla M.L.
Format Journal Article
LanguageEnglish
Published Hoboken, NJ Wiley-Blackwell 15.08.2014
Wiley Subscription Services, Inc
Subjects
Antineoplastic Agents - adverse effects
Biological and medical sciences
Breast Neoplasms - blood
Breast Neoplasms - complications
Breast Neoplasms - drug therapy
Cancer
Drug Monitoring - methods
Everolimus
Female
Humans
Lung Diseases, Interstitial - blood
Lung Diseases, Interstitial - etiology
Medical research
Medical sciences
Mucin-1 - blood
Mucin-1 - immunology
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Pneumology
Respiratory system : syndromes and miscellaneous diseases
Sirolimus - adverse effects
Sirolimus - analogs & derivatives
Treatment Outcome
Tumors
Human
Lung disease
Breast disease
Respiratory disease
Antigen CA 15 3
Lactone
Breast cancer
Tumoral marker
Malignant tumor
Macrolide
Mammary gland diseases
Cancerology
Treatment
Cause
Interstitial pneumonitis
Advanced stage
Protein synthesis inhibitor
Immunosuppressive agent
Everolimus
Cancer
Online AccessGet full text

Cover

More Information
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.28714